## Answer
(model generated chain of thought explanation)

Given that the patient has acute decompensated congestive heart failure (CHF) and is being treated with a medication that targets beta-1 adrenergic receptors preferentially over beta-2 adrenergic receptors, we can deduce the following:

1. The medication's mechanism of action suggests it is a beta-blocker.
2. Beta-blockers are known to have a negative inotropic effect (decrease contractility) and chronotropic effect (slowing heart rate), which would exacerbate symptoms of CHF such as shortness of breath, lower leg edema, and fatigue.
3. The fact that the medication's efficacy decreases within one week due to receptor downregulation supports this deduction.

Considering these points, let's evaluate the options:

A. Epinephrine - This is a catecholamine with both beta-1 and beta-2 adrenergic effects. It would increase heart rate and contractility, which would worsen CHF symptoms.
B. Isoproterenol - This is also a beta-adrenergic agonist that primarily stimulates beta-2 receptors. Like epinephrine, it would increase heart rate and contractility, exacerbating CHF symptoms.
C. Norepinephrine - This is another catecholamine with both alpha and beta adrenergic effects. It has a strong vasoconstrictive effect, which could worsen edema in the lower legs.
D. Dobutamine - This medication is a beta-1 selective adrenergic agonist that also has some alpha-adrenergic activity. However, it has a unique property of having minimal effects on heart rate and contractility compared to other beta-blockers. It can be used as an inotrope (increases cardiac output) in the setting of acute decompensated CHF.

Given the patient's condition and the medication's mechanism of action, dobutamine is the most appropriate choice because it targets beta-1 adrenergic receptors preferentially over beta-2 adrenergic receptors, which aligns with the prescribed treatment. It also has a more favorable side effect profile compared to other options.

Therefore, the answer is D.